9 studies found for:    motavizumab
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) Season
Conditions: Respiratory Syncytial Virus Infections;   Chronic Lung Disease and <= 24 Months of Age or;   Premature With Gestational Age <=35 Weeks and <=6 Months of Age
Interventions: Biological: Motavizumab, palivizumab;   Biological: Palivizumab, motavizumab;   Biological: Motavizumab
2 Completed
Has Results
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children
Condition: Motavizumab Administration for a Second Season for RSV Prophylaxis
Interventions: Biological: motavizumab (MEDI-524);   Biological: palivizumab 15 mg/kg
3 Completed
Has Results
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: motavizumab (MEDI-524);   Biological: palivizumab
4 Completed A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness
Condition: Respiratory Syncytial Virus (RSV)
Interventions: Biological: Motavizumab;   Other: Biological/Vaccine: Motavizumab;   Other: Placebo
5 Completed
Has Results
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
Condition: Congenital Heart Disease
Interventions: Biological: Motavizumab;   Biological: Palivizumab
6 Withdrawn A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants
Condition: Wheezing
Interventions: Biological: Motavizumab;   Other: Placebo
7 Completed A Study to Evaluate a Single IM Dose of Motavizumab Treatment of Children With RSV (Respiratory Syncytial Virus) Illness
Condition: Healthy
Interventions: Biological: MEDI-524;   Other: Placebo
8 Completed MEDI-524 (Motavizumab) for the Prevention of Respiratory Syncytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States
Condition: Healthy
Interventions: Biological: MEDI-524;   Other: Placebo
9 Completed A Phase I, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557
Condition: Healthy
Intervention: Biological: MEDI-557

Indicates status has not been verified in more than two years